HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: 2353040332v1 235/3/892    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shankar, S. Articles by Demetri, G. D. Search for Related Content PubMed PubMed Citation Articles by Shankar, S. Articles by Demetri, G. D.

Gastrointestinal Stromal Tumor: New Nodule-within-a-Mass Pattern of Recurrence after Partial Response to Imatinib Mesylate¹

¹ From the Departments of Radiology (S.S., E.v.S., P.J.D., A.V.D.A.) and Adult Oncology (G.D.D.), Dana-Farber Cancer Institute, Harvard Medical School, Boston, Mass; and Department of Radiology, Brigham and Women’s Hospital, Boston, Mass (S.S., E.v.S., P.J.D., A.V.D.A.). From the 2002 RSNA Annual Meeting. Received February 27, 2004; revision requested May 5; revision received August 19; accepted September 8. Address correspondence to S.S., Department of Radiology, University of Massachusetts Medical Center, 55 Lake Ave North, Worcester, MA 01655 (e-mail: shankars@ummhc.org).

PURPOSE: To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial reponse to imatinib mesylate.

MATERIALS AND METHODS: Ninety-two patients with metastatic GIST who underwent treatment in a clinical trial with oral imatinib mesylate were followed up for 29 months. An institutional review board–approved protocol was used. The study complied with the Health Insurance Portability and Accountability Act, and written informed consent was obtained from all patients. Images of the chest, abdomen, and pelvis, acquired with computed tomography (CT), positron emission tomography (PET), and, in some cases, magnetic resonance imaging, were evaluated for treatment response and disease recurrence. Thirty-nine patients (29 men, 10 women; age range, 18–84 years; mean, 49.2 years) had recurrent disease after an initial variable period of response (range, 2–24 months; median, 14.4 months). Initial response was determined with findings of decreased uptake of fluorine 18 fluorodeoxyglucose at PET, shrinkage of tumor, and decreased attenuation at CT. Images were evaluated for disease recurrence by two experienced radiologists who were blinded to each other’s interpretation but not to clinical details. Final reading was performed by consensus.

RESULTS: A nodule within a mass was seen in 21 of 39 patients (in intrahepatic tumor [n = 8], extrahepatic tumor [n = 10], or both intra- and extrahepatic tumors [n = 3]) and was the first sign of disease progression in 17 of 21 patients. Other patterns of recurrence included new site of disease (n = 7), regrowth of preexistent lesion (n = 20), and mixed (more than one) pattern (n = 9). Disease progression was verified at needle biopsy (n = 16), follow-up imaging (n = 14), and/or surgical resection (n = 9).

CONCLUSION: A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.

© RSNA, 2005

This article has been cited by other articles:

				C. Suzuki, H. Jacobsson, T. Hatschek, M. R. Torkzad, K. Boden, Y. Eriksson-Alm, E. Berg, H. Fujii, A. Kubo, and L. Blomqvist Radiologic Measurements of Tumor Response to Treatment: Practical Approaches and Limitations RadioGraphics, March 1, 2008; 28(2): 329 - 344. [Abstract] [Full Text] [PDF]

				J. Desai, S. Shankar, M. C. Heinrich, J. A. Fletcher, C. D. Fletcher, J. Manola, J. A. Morgan, C. L. Corless, S. George, K. Tuncali, et al. Clonal Evolution of Resistance to Imatinib in Patients with Metastatic Gastrointestinal Stromal Tumors Clin. Cancer Res., September 15, 2007; 13(18): 5398 - 5405. [Abstract] [Full Text] [PDF]

				R. H. I. Andtbacka, C. S. Ng, C. L. Scaife, J. N. Cormier, K. K. Hunt, P. W. T. Pisters, R. E. Pollock, R. S. Benjamin, M. A. Burgess, L. L. Chen, et al. Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib Ann. Surg. Oncol., January 1, 2007; 14(1): 14 - 24. [Abstract] [Full Text] [PDF]

				H. Kuehl, P. Veit, S. J. Rosenbaum, A. Bockisch, and G. Antoch Can PET/CT Replace Separate Diagnostic CT for Cancer Imaging? Optimizing CT Protocols for Imaging Cancers of the Chest and Abdomen J. Nucl. Med., January 1, 2007; 48(1_suppl): 45S - 57S. [Abstract] [Full Text] [PDF]

				E. Wardelmann, S. Merkelbach-Bruse, K. Pauls, N. Thomas, H.-U. Schildhaus, T. Heinicke, N. Speidel, T. Pietsch, R. Buettner, D. Pink, et al. Polyclonal Evolution of Multiple Secondary KIT Mutations in Gastrointestinal Stromal Tumors under Treatment with Imatinib Mesylate. Clin. Cancer Res., March 15, 2006; 12(6): 1743 - 1749. [Abstract] [Full Text] [PDF]